Literature DB >> 16690953

Saccharomyces boulardii produces in rat small intestine a novel protein phosphatase that inhibits Escherichia coli endotoxin by dephosphorylation.

Jean-Paul Buts1, Nadine Dekeyser, Catherine Stilmant, Emilie Delem, Francoise Smets, Etienne Sokal.   

Abstract

Using a polyclonal antibody raised against a highly conserved sequence of 38 amino acids containing the activation site (VTDSAAGAT) common to mammalian and yeast alkaline phosphatases (AP), we identified in decapsidated Saccharomyces boulardii a protein phosphatase detected by autoradiography as a single signal (63 kD). Using an affinity chromatography column, the protein phosphatase could be concentrated 39.1-fold and presented as a doublet of two subunits. Compared with rat and bovine purified intestinal AP, the enzyme from S. boulardii had a greater ability to dephosphorylate the lipopolysaccharide (LPS) of Escherichia coli 055B5. When tested in vivo, intraperitoneal injection of intact LPS to rats produced, after 9 h, 100 ng/mL of circulating tumor necrosis factor-alpha with inflammatory lesions and apoptotic bodies in the liver and the heart, whereas rats injected with partially dephosphorylated LPS produced only 40 ng/mL tumor necrosis factor-alpha without organic lesions. In conclusion, S. boulardii is able to inhibit toxicity of E. coli surface endotoxins by the release of a protein phosphatase exhibiting a great capacity of dephosphorylation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16690953     DOI: 10.1203/01.pdr.0000220322.31940.29

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  30 in total

Review 1.  Systematic review and meta-analysis of Saccharomyces boulardii in adult patients.

Authors:  Lynne V McFarland
Journal:  World J Gastroenterol       Date:  2010-05-14       Impact factor: 5.742

Review 2.  Bacterial-fungal interactions: hyphens between agricultural, clinical, environmental, and food microbiologists.

Authors:  P Frey-Klett; P Burlinson; A Deveau; M Barret; M Tarkka; A Sarniguet
Journal:  Microbiol Mol Biol Rev       Date:  2011-12       Impact factor: 11.056

Review 3.  Twenty-five years of research on Saccharomyces boulardii trophic effects: updates and perspectives.

Authors:  Jean-Paul Buts
Journal:  Dig Dis Sci       Date:  2008-06-05       Impact factor: 3.199

Review 4.  Commensal Fungi in Health and Disease.

Authors:  Jose J Limon; Joseph H Skalski; David M Underhill
Journal:  Cell Host Microbe       Date:  2017-08-09       Impact factor: 21.023

5.  Unique Probiotic Properties and Bioactive Metabolites of Saccharomyces boulardii.

Authors:  JunJie Fu; Jun Liu; XuePing Wen; Guirong Zhang; Ji Cai; Zongwei Qiao; Zheming An; Jia Zheng; Li Li
Journal:  Probiotics Antimicrob Proteins       Date:  2022-05-24       Impact factor: 4.609

Review 6.  Do you have a probiotic in your future?

Authors:  Maria G Dominguez-Bello; Martin J Blaser
Journal:  Microbes Infect       Date:  2008-08-13       Impact factor: 2.700

Review 7.  Review article: anti-inflammatory mechanisms of action of Saccharomyces boulardii.

Authors:  C Pothoulakis
Journal:  Aliment Pharmacol Ther       Date:  2008-07-23       Impact factor: 8.171

Review 8.  Saccharomyces boulardii in childhood.

Authors:  Yvan Vandenplas; Oscar Brunser; Hania Szajewska
Journal:  Eur J Pediatr       Date:  2008-12-19       Impact factor: 3.183

9.  Saccharomyces boulardii inhibits lipopolysaccharide-induced activation of human dendritic cells and T cell proliferation.

Authors:  S Thomas; I Przesdzing; D Metzke; J Schmitz; A Radbruch; D C Baumgart
Journal:  Clin Exp Immunol       Date:  2009-01-21       Impact factor: 4.330

10.  Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders.

Authors:  Theodoros Kelesidis; Charalabos Pothoulakis
Journal:  Therap Adv Gastroenterol       Date:  2012-03       Impact factor: 4.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.